#Amyloid

Drugs designed to clear amyloid beta from the brain—once seen as a promising path to slowing Alzheimer’s—may not actually help patients in any meaningful way, according to a major review of over 20,000 participants.…

At WIRED Health, pioneering Alzheimer's researcher John Hardy outlined the stakes—and next steps—of where treatment is headed next.

Part the First: Anti-amyloid Antibodies and Alzheimer’s Disease (AD). A Cochrane review of monoclonal antibodies targeting amyloid plaques in AD has found that these drugs have little to no effect on cognitive function of AD patients.…

Boosting the brain's waste-disposal system is increasingly showing promise for Alzheimer's disease, with a study now suggesting that a novel approach eases brain deficits and symptoms associated with the condition

For decades, scientists have concentrated on what now looks to be a blind alley.